Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$41.71 USD

41.71
3,332,742

+0.28 (0.68%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mylan Down 24% Year to Date: What's Troubling the Stock?

by Zacks Equity Research

Shares of Mylan N.V. (MYL) have declined 24.7% in the last six months compared to the industry's loss of 20%.

    Novartis Poised to Grow on Oncology Portfolio & Biosimilars

    by Zacks Equity Research

    Novartis expects the next growth phase to begin in 2018 driven by Cosentyx Entresto, Kisqali and Kymriah.

      Roche (RHHBY) Announces Positive Data on Leukemia Drug

      by Zacks Equity Research

      Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta.

        Novartis Announces Positive Data on Urticaria Drug Xolair

        by Zacks Equity Research

        Novartis AG (NVS) announced new positive data on chronic spontaneous urticaria (CSU) drug Xolair from a phase IIIb study, OPTIMA.

          Roche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA

          by Zacks Equity Research

          Roche Holdings AG (RHHBY) announced that the FDA has put a partial clinical hold on a phase Ib and phase I/II b trials evaluating immunotherapy drug Tecentriq.

            Oncology Space in Focus this Week on ESMO Presentations

            by Zacks Equity Research

            There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.

              Amgen/Allergan's Avastin Biosimilar Secures FDA Approval

              by Zacks Equity Research

              The FDA approves Amgen-Allergan's biosimilar version of Roche's Avastin for treating multiple types of cancers, to be marketed by the trade name of Mvasi.

                Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE

                by Zacks Equity Research

                Bristol-Myers Squibb Company (BMY) enters into a collaboration and license agreement with Halozyme Therapeutics, Inc. (HALO).

                  Roche (RHHBY) Announces Data on Respiratory Drug Esbriet

                  by Zacks Equity Research

                  Roche Holdings AG (RHHBY) announced results from a six-month study combining idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone) and Ofev.

                    Nektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate

                    by Zacks Equity Research

                    Nektar (NKTR) initiates phase I/II combo study on lead candidate NKTR-214 along with Tecentriq and Keytruda. The trial complements Nektar's ongoing PIVOT research clubbed with Opdivo.

                      Array's NDAs for Melanoma Combo Accepted for Review by FDA

                      by Zacks Equity Research

                      Array BioPharma's (ARRY) new drug applications for the combination of binimetinib and encorafenib to treat melanoma, accepted for review by the FDA.

                        Novartis' BLA for Biosimilar of Rituxan Accepted by the FDA

                        by Zacks Equity Research

                        Novartis AG (NVS) announced that the FDA accepted its Biologics License Application for a proposed biosimilar version of Roche Holding AG's (RHHBY) Rituxan.

                          Roche's Ophthalmology Drug Fails to Meet Primary Endpoint

                          by Zacks Equity Research

                          Roche's (RHHBY) share price declined after its ophthalmology candidate, lampalizumab, failed to meet the primary endpoint in phase III Spectri study.

                            AbbVie Submits NDA for Endometriosis Candidate to the FDA

                            by Zacks Equity Research

                            AbbVie Inc. (ABBV) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA.

                              MEI Pharma-Presage Biosciences on License Deal for Voruciclib

                              by Zacks Equity Research

                              MEI Pharma (MEIP) signs a license contract with Presage Biosciences to develop its CDK inhibitor, voruciclib, by dint of which, it nabs exclusive rights to the oncology candidate.

                                4 Drug Stocks Worth a Look on Promising Cancer Pipeline

                                by Zacks Equity Research

                                Cancer is the second most common cause of death in the U.S. preceded only by heart disease. We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

                                  Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda

                                  by Zacks Equity Research

                                  Incyte Corporation (INCY) announced new and updated data from the ongoing phase I/II ECHO-202 trial on pipeline candidate epacadostat with Keytruda.

                                    Parkinson's Now a Hot Therapeutic Area: What's Up Lately?

                                    by Zacks Equity Research

                                    Parkinson's disease is a lucrative area due to lack of curative therapy in this space. Many players are trying to bring new treatments to the market. A lot has happened in last couple of months.

                                      Roche's (RHHBY) Actemra Gets FDA Nod for Label Expansion

                                      by Zacks Equity Research

                                      Roche Holding AG's (RHHBY) drug Actemra got FDA approval for label expansion.

                                        Immunogen Inks Deal With Jazz Pharma to Develop ADC Molecule

                                        by Zacks Equity Research

                                        ImmunoGen (IMGN) and Jazz Pharma announced a strategic collaboration to develop and commercialize antibody-drug conjugate products.

                                          AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug

                                          by Zacks Equity Research

                                          AstraZeneca (AZN) and Takeda Pharmaceutical Company entered into an agreement to jointly develop and commercialize MEDI1341 for the potential treatment of Parkinson's disease.

                                            Merck's CETP Inhibitor Reduces Cardiovascular Risk by 9%

                                            by Zacks Equity Research

                                            Detailed results from Merck's (MRK) REVEAL study on anacetrapib, showed that the CETP inhibitor and a statin reduced the risk of major coronary events by 9% relative to placebo.

                                              Roche's Gazyva Gets Priority Review for Follicular Lymphoma

                                              by Zacks Equity Research

                                              Roche Holding AG (RHHBY) announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to leukaemia drug Gazyva.

                                                Novartis Announces Positive Data on Cardiovascular Drug

                                                by Zacks Equity Research

                                                Novartis AG (NVS) announced positive primary data on pipeline candidate canakinumab (ACZ885).

                                                  Swarup Gupta headshot

                                                  Foreign Stock Roundup: WPP 1H17, BHP Billiton Fiscal 2017 Results Impress

                                                  by Swarup Gupta

                                                  Foreign markets remained focused on the outcome of the annual economic symposium at Jackson Hole last week.